Quoin Pharmaceuticals Expands Netherton Syndrome Clinical Studies Internationally; First Site to Open in Saudi Arabia; Engages Experienced Local Clinical Research Organization; Plans for Additional Sites at Advanced Stage
Portfolio Pulse from Benzinga Newsdesk
Quoin Pharmaceuticals is expanding its clinical studies for Netherton Syndrome internationally, with the first site opening in Saudi Arabia. The company has engaged an experienced local clinical research organization and plans for additional sites are at an advanced stage.
June 27, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Quoin Pharmaceuticals is expanding its clinical studies for Netherton Syndrome internationally, starting with a site in Saudi Arabia. This expansion could accelerate the development and potential approval of their treatment.
The expansion of clinical studies internationally, especially with the first site in Saudi Arabia, indicates progress in the development of Quoin Pharmaceuticals' treatment for Netherton Syndrome. This could lead to faster approval and market entry, positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100